PROTON-PUMP INHIBITOR USE AND POTENTIAL DRUG INTERACTIONS IN OUTPATIENTS
نویسندگان
چکیده
منابع مشابه
When is proton pump inhibitor use appropriate?
Proton pump inhibitor (PPI) therapy is commonly used outside of Food and Drug Administration indication for a broad range of conditions such as extra-esophageal reflux and PPI-responsive esophageal eosinophilia. While this may be appropriate in some scenarios, it has also resulted in widespread inappropriate PPI use. At the same time, data suggesting adverse effects of long-term PPI therapy are...
متن کاملPotential Drug Interactions in War-Injured Veterans
Drug-drug interaction (DDI) is one of the most important problems in the treatment of patients suffering from different chronic intractable diseases. The war-injured veterans are one of the groups that are prone to chronic refractory diseases. This investigation was conducted on war-injured veterans treated in a multi-disciplinary clinic in Tehran. Using Poisson model, a total of 150 patients w...
متن کاملDetection of Potential Drug-Drug Interactions for Outpatients across Hospitals
The National Health Insurance Administration (NHIA) has adopted smart cards (or NHI-IC cards) as health cards to carry patients' medication histories across hospitals in Taiwan. The aims of this study are to enhance a computerized physician order entry system to support drug-drug interaction (DDI) checking based on a patient's medication history stored in his/her NHI-IC card. For performance ev...
متن کاملAdvantages and Disadvantages of Long-term Proton Pump Inhibitor Use
Proton pump inhibitors (PPIs) potently inhibit gastric acid secretion and are widely used for treatment of acid-related diseases including gastroesophageal reflux disease and secondary prevention of aspirin/NSAID-induced ulcers. Although clinically important adverse effects of PPIs can occur, just as with other drugs, those are not frequently observed during or after administration. Thus, PPIs ...
متن کاملProton - pump inhibitor - responsive esophageal
Recent findings Several prospective series have reported consistent rates of PPI-REE (30–40%) in adults with suspected EoE. At baseline, PPI-REE and EoE have been shown to be indistinguishable upon clinical, endoscopic, and molecular characteristics [eotaxin-3, interleukin (IL-5), and IL-13 expression]. PPI therapy partially restores esophageal mucosal integrity in PPI-REE, but not in EoE. Anti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Applied Pharmaceutics
سال: 2018
ISSN: 0975-7058
DOI: 10.22159/ijap.2018.v10s1.79